Project Objective: Clinical Trial, Phase 1 or Phase 1/2
The City of Hope Alpha Clinic: A roadmap for equitable and inclusive access to regenerative medicine therapies for all Californians
City of Hope has long developed groundbreaking therapies, and building on that success we want to democratize cancer care by bringing therapies to patients rather than making them come to us. This will ensure that all Californians have the same access to cutting-edge care. The Alpha Clinic Network is committed to ensuring equitable access to […]
A comprehensive stem cell and gene therapy clinic to advance new therapies for a diverse patient population in California
We aim to markedly expand access of all Californians to outstanding cell and gene therapy trials for multiple conditions with unmet treatment needs. We will also contribute with excellence to the other network sites in advancing all aspects of regenerative medicine. As an ASCC, we will help advance the field for multiple diseases with unmet […]
University of California, San Francisco (UCSF) Alpha Stem Cell Clinic (ASCC)
We propose cell and gene therapy trial infrastructure that will focus on hereditary hematological and immunologic disorders and on anti-inflammatory lung disorders. This alpha stem cell clinic operation at UCSF will expand access to these novel cell and gene therapies to California citizens . The objective of this proposal from the Univ. of Calif., San […]
The Stanford Alpha Stem Cell Clinic
Our project objective is to develop a sustainable infrastructure and become a Northern California hub for stem cell therapies, thus both reducing current patient burden and increasing access to this treatment modality for patients with unmet medical needs. A major roadblock in stem cell therapies is confirming their efficacy in patients. The Alpha Clinic will […]
University of California, San Francisco (UCSF) CIRM Alpha Stem Cell Clinic
We propose a cellular trial operation at UCSF that will focus on childhood hereditary hematological and immunologic disorders and in anti-inflammatory lung cellular therapies. This alpha clinic operation at UCSF will expand participation by California citizens in these novel clinical themes. The objective of this proposal from the Univ. of Calif., San Francisco is to […]
University of California, San Francisco (UCSF) CIRM Alpha Stem Cell Clinic
We propose a cellular trial operation at UCSF that will focus on childhood hereditary hematological and immunologic disorders and in anti-inflammatory lung cellular therapies. This alpha clinic operation at UCSF will expand participation by California citizens in these novel clinical themes. The objective of this proposal from the Univ. of Calif., San Francisco is to […]
Alpha Stem Cell Clinic for Northern and Central California
The UC Davis Alpha Clinic will provide pivotal resources to assist in the approval & conducting of stem cell/regenerative medicine clinical trials. A centralized space & personnel to administer the therapies to patients in the UCD 33-county catchment region (~6 million people in Northern/Central CA) Thanks to infrastructure & funding provided by CIRM, stem cell/regenerative […]
A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus
Therapeutic Candidate or Device iPSC-derived CD19 CAR T cell therapy Indication Systemic Lupus Erythematosus Therapeutic Mechanism Depletion of CD19+ B cells and plasmablasts Unmet Medical Need Potential for drug-free remission and reset of the immune system Project Objective Phase 1 trial completed Major Proposed Activities Site Activation and Patient Enrollment Clinical Trial Data Monitoring, Database […]
Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies
Therapeutic Candidate or Device SENTI-202 is an allogeneic off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cellular therapy targeting CD33 and/or FLT3 malignancies. Indication CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Therapeutic Mechanism SENTI-202 has been designed to incorporate a logic gated gene circuit and an engineered […]
Autologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis
Therapeutic Candidate or Device NXC-201 Indication AL Amyloidosis Therapeutic Mechanism Genetically modified T-cell targeting B-cell maturation antigen (BCMA) Unmet Medical Need Amyloid light-chain (AL) amyloidosis is a devastating, rare plasma cell disorder that results in organ deposition. In the US, there are ~3,972 diagnoses every year. Currently, there is no cure for AL amyloidosis. Project […]